Unlocking the Key to Overcoming RNA Virus Infections: A Dynamic Regulatory Network of MicroRNAs and Next-Generation Antiviral Strategies
Background
RNA viruses are a diverse group of pathogens characterized by high mutation rates and efficient utilization of host cell mechanisms, leading to significant morbidity and mortality worldwide. These viruses, such as SARS, MERS, and COVID-19, constantly mutate, rendering existing treatments ineffective. Conventional antiviral drugs primarily target viral-specific enzymes or proteins. However, this approach suffers from the critical limitation of rapidly developing drug resistance due to the virus's genetic variability.
To address these challenges, alternative strategies that leverage the host cell's regulatory systems have emerged. MicroRNAs (miRNAs) are key regulators of gene expression within cells, playing a crucial role in modulating the complex interactions between the host and the virus at the post-transcriptional level. Research has revealed that miRNAs exert a significant influence on various aspects of infection, including viral replication, immune responses, and disease progression. Previous studies have often analyzed the roles of individual miRNAs by categorizing them as either antiviral (suppressing the virus) or proviral (promoting viral replication). However, this simplistic dichotomy fails to fully capture the multifaceted and context-dependent behavior of miRNAs during infection.
Key Findings
The framework presented in this study provides a comprehensive analysis of miRNA-virus interactions, establishing criteria for utilizing miRNAs in precision medicine. The researchers focus on analyzing the complex mechanisms by which miRNAs directly target and degrade viral RNA or regulate host dependency factors essential for viral replication. Antiviral signaling pathways and immune control mechanisms are also included in the analysis. Based on these mechanistic studies, a new functional classification system is established, moving beyond the conventional binary classification.
In particular, the developed therapeutic decision framework is designed to enable the selection of personalized antiviral treatment strategies by utilizing information on the functional classification of miRNAs activated in specific infection environments. For example, treatment components are administered differently based on the patient's condition and the viral genome's mutation profile. Specifically, miRNA mimics are used to enhance inhibitory functions, and anti-miRs are used to block harmful reactions. Furthermore, RNA interference (RNAi) and CRISPR-based technologies are integrated to improve target control performance.
In drug delivery systems, lipid nanoparticles (LNPs) and exosome-based technologies are primarily being considered. The goal is to address challenges such as low delivery efficiency, lack of tissue specificity, and off-target effects. In line with this, systems biology approaches that organically combine multi-omics data integration, single-cell transcriptomics, spatial transcriptomics, network analysis, and artificial intelligence (AI) are gaining traction. By using this analytical network to identify key miRNA regulatory hubs that influence drug response, it will be possible to lay the foundation for personalized precision antiviral therapy.
Significance and Prospects
This study is valuable because it redefines miRNAs not as mere byproducts of infection, but as central regulators of viral replication and host defense mechanisms. By transcending the limitations of conventional single-target antiviral drugs, it lays the foundation for multifaceted therapeutic approaches that modulate host regulatory networks. This therapeutic model has the potential to be expanded into a versatile platform that can flexibly address highly variable RNA viruses such as influenza and coronaviruses.
However, there are many hurdles to overcome before achieving practical results in the clinical setting. Although LNP and exosome-based delivery methods have been proposed, the challenge remains to maximize targeted delivery efficiency to specific tissues. Technologies to control off-target effects and associated toxicity risks that may occur due to the inhibition of unintended genes also need to be improved. Systems biology-based AI analysis must also be validated with large-scale clinical data to ensure treatment reliability. Nevertheless, the potential for developing next-generation antiviral therapeutics that exploit host regulatory mechanisms is expected to be a major milestone in changing the paradigm of infectious disease response.
RNA viruses are a diverse and rapidly evolving group of pathogens that significantly contribute to worldwide morbidity and mortality, propelled by elevated mutation rates and effective use of host cellular mechanisms. MicroRNAs (miRNAs) have emerged as an essential post-transcriptional regulator of host-virus interactions, influencing viral replication, immunological responses and disease progression. This review offers a comprehensive overview of the miRNA-virus axis in RNA virus infections, highlighting the dynamic and context-dependent roles of host miRNAs. We investigate the mechanistic basis of miRNA-mediated regulation, including direct targeting of viral RNA, modulation of host dependency factors, regulation of antiviral signaling pathways, and immune-mediated effects on infection outcomes. We propose a functional categorization of miRNAs that transcends the conventional antiviral-proviral dichotomy, facilitating a more accurate comprehension of their involvement in various infection settings. This review connects mechanistic insights with translational applications by outlining novel treatment techniques, such as miRNA mimics, anti-miRs, RNA interference, and CRISPR-based methodologies. We also propose a therapeutic decision framework that links miRNA functional classification with targeted antiviral interventions. Key challenges including delivery efficiency, tissue specificity, and off-target effects are also discussed, with emphasis on lipid nanoparticles and exosome-based delivery systems. We further highlight the role of systems biology approaches, including multi-omics integration, single-cell and spatial transcriptomics, network analysis, and artificial intelligence, in identifying regulatory miRNA hubs and enabling precision antiviral medicine. Collectively, this review reinterprets the miRNA-virus axis as a dynamic regulatory network and provides a translational framework for the development of next-generation antiviral therapeutics.
The framework presented in this study can contribute to accelerating the development of therapeutics and improving clinical success rates in the event of an infectious disease outbreak. A specific application scenario involves the rapid collection of single-cell transcriptomic data from patients during a novel RNA virus outbreak. Clinicians can then use an AI analysis platform to understand the patient's infection status and identify key miRNA hubs that serve as optimal therapeutic targets. Subsequently, a personalized LNP cocktail containing selected miRNA mimics or anti-miRs can be administered to the patient.
This approach reduces the significant time and cost associated with traditional small-molecule drug development, as only the RNA sequence of the therapeutic needs to be rapidly redesigned in response to viral mutations. If safe and effective LNP or exosome delivery platforms are already established, a defense system that can respond immediately to novel viruses can be easily implemented. As a result, a dynamic defense system that provides treatment before the emergence of resistant viruses is expected to be industrially realized.